Vitamin D has been connected with increased intramyocellular lipid (IMCL) mitochondrial function in skeletal muscle. It is also shown to prevent lipotoxicity in several tissues, but this has not yet been examined in skeletal muscle. Perilipin 2 (PLIN2), a lipid droplet protein upregulated with vitamin D treatment, is integral to managing IMCL capacity and lipid oxidation in skeletal muscle. Increased lipid storage and oxidation is associated with increased tolerance to a hyperlipidic environment and resistance to lipotoxicity. Therefore, I hypothesized that vitamin D increases β-oxidation and lipid turnover though a PLIN2 mediated mechanism, thereby preventing lipotoxicity. This hypothesis was divided into two specific aims: 1) Characterize the effect of vitamin D and PLIN2 on lipid turnover and β-oxidation in mature myotubes, and 2) Determine the role of vitamin D and PLIN2 in regulating key markers of lipotoxicity. To address these aims, cells were treated with or without vitamin D, palmitate, and PLIN2 siRNA in an eight group, 2x2x2 design. Key experiments included quantitative real time polymerase chain reaction for markers of lipid accumulation, lipolysis, and lipotoxicity; Seahorse oxygen consumption assay; 14C-palmitate oxidation assay; and analyses of lipid accumulation and profile. Failure of the palmitate treatment to produce a reliable model for lipotoxicity resulted in negative data for Aim 2 of this dissertation and a focus on vitamin D and PLIN2 knockdown treatments as a four group, 2x2 model. Aim 1 showed that vitamin D reliably increases markers of lipolysis and lipid accumulation. Most of these markers were in turn decreased after PLIN2 knockdown, and DGAT2 exhibited an interaction effect between the two treatments. Contrary to our hypothesis and some published research, PLIN2 knockdown did not prevent lipid accumulation. Vitamin D increased oxygen consumption, especially consumption driven by mitochondrial complex II. PLIN2 knockdown decreased oxygen consumption and demonstrated an interaction effect specific to mitochondrial complex II. Data in this dissertation show that vitamin D increases mitochondrial function, and these effects are at least in part accomplished through a PLIN2 mediated mechanism. However, this work lacks the data required to make specific claims regarding β-oxidation and lipid turnover. This research is some of the first to show that PLIN2 knockdown carries negative impacts for skeletal muscle mitochondria and makes valuable contributions to general knowledge of how vitamin D and lipid storage impact muscle health and function. This ultimately provides additional evidence to advocate for vitamin D supplementation as a means of improving musculoskeletal health and function. Future research should investigate how vitamin D and PLIN2 impact markers of lipotoxicity in skeletal muscle.

<p>The <italic>Chlamydiaceae</italic> are Gram-negative, obligate intracellular bacteria that are significant pathogens of humans and animals. Intracellularly, the bacteria reside in a membrane-bound vacuole, called the inclusion, from which they manipulate host processes to create a niche optimal for survival and propagation. Acquisition of host-derived lipids is essential for chlamydial growth, yet the source of lipids and mechanisms of trafficking to the inclusion are not well-established. The inclusion avoids interaction with several classical membrane and lipid transport pathways. In a functional genomic screen to identify host modulating chlamydial proteins, our lab identified cytosolic lipid droplets (LDs) as potential target organelles of <italic>Chlamydia</italic>. LDs are postulated to function in many cellular processes, such as lipid metabolism and transport, membrane trafficking, and cell signaling; therefore, we hypothesized that LDs may be important for <italic>Chlamydia</italic> pathogenesis as a source of lipids or as a platform for regulating other cellular functions. Here, we characterize the interaction between eukaryotic LDs and the chlamydial inclusion.</p><p> We find that LDs are recruited to the <italic>Chlamydia</italic> inclusion, chlamydial infection disrupts neutral lipid homeostasis, and pharmacological prevention of LD formation inhibits chlamydial replication. <italic>Chlamydia</italic> produces proteins (Ldas) that localize with LDs in yeast and mammalian cells when transiently expressed and are exported out of the inclusion to peripheral lipid-rich structures during infection. By electron microscopy and live cell imaging, we observe the translocation of intact LDs into the <italic>Chlamydia</italic> inclusion lumen. Biochemical and microscopic analysis of LDs from infected cells reveals that LD translocation may occur at specialized subregions of the inclusion membrane. The <italic>Chlamydia</italic> Lda3 protein is implicated in LD tethering to the inclusion membrane, and displacement of the protective coat protein, ADRP, from LD surfaces. This phenomenon could provide access for lipases to the LD core for utilization by the replicating bacteria. Additionally, the functional domains of Lda3 involved in binding to LD and inclusion membranes are identified. </p><p> In these studies, we identify eukaryotic lipid droplets (LDs) as a novel target organelle important for <italic>Chlamydia</italic> pathogenesis and describe a unique mechanism of whole organelle sequestration not previously observed for bacterial pathogens. These results represent a fundamental shift in our understanding of host interactions with the chlamydial inclusion, and may represent a new area for research in the field of cellular microbiology.</p> / Dissertation

Metabolic energy is most efficiently stored as triacylglycerol (TAG). This neutral lipid accumulates mainly within adipose tissues, but it can be stored and used in all types of cells. Within cells it is packed in organelles called lipid droplets (LDs). They consist of a core of neutral lipids like TAG and cholesterol esters, which is surrounded by a phospholipid monolayer that mainly consists of phosphatidylcholine (PC). Attached to or inserted into this monolayer are various proteins, mainly LD specific structural proteins or lipid metabolic enzymes. Though excess uptake of nutrition leads to lipid accumulation in all kinds of body tissues, which is accompanied by the augmentation of LDs and results in cellular dysfunction and the development of metabolic diseases, relatively little is known about the biogenesis and growth of LDs. This thesis focuses on diacylglycerol acyltransferase 2 (DGAT2), an enzyme of the TAG biosynthetic pathway, and on lyso-phosphatidylcholine acyltransferases 1 and 2 (LPCAT1 and LPCAT2), both enzymes of one of the PC biosynthetic pathways called Lands cycle. The data presented in this thesis show that these enzymes can localize to LDs and that they actively synthesize TAG and PC at the surface of LDs. While the LPCATs reside on LDs independent from the nutrition status of the cell, DGAT2 accumulates on LDs upon excess availability of oleic acid. DGAT2, LPCAT1 and LPCAT2 differ in their structure from other iso-enzymes that catalyze the same reactions. This thesis shows that they exhibit a monotopic conformation and that they contain a hydrophobic stretch that presumably forms a hairpin. This topology enables them to localize to both a phospholipid bilayer like the membrane of the endoplasmic reticulum and to a phospholipid monolayer like the surface of LDs. The different biophysical properties of the structures of iso-enzymes might be responsible for their subcellular localization and the formation of distinct TAG or PC pools that are destined for different purposes. This would explain, why the iso-enzymes are often not able to replace each other. Knock-down and overexpression experiments performed in this thesis show that the activity of LPCAT1, LPCAT2 and DGAT2 influence the packaging of lipids within LDs. Knock-down of LPCAT1 and LPCAT2 leads to an increase in LD size without concomitant increase in the amount of TAG. Combined with the finding that the profile of the PC species of the LD surface reflects the substrate preferences of LPCAT1 and LPCAT2, the results suggest that these enzymes are responsible for the formation of the LD surface. Therefore, the increase in LD size upon LPCAT1 and LPCAT2 knock-down results from an adjustment of the surface-to-volume ratio in response to reduced availability of surface lipids. The connection between LPCATs and LD size was corroborated in the model organism Drosophila melanogaster. Three different knockout fly strains of the Drosophila homologue of LPCAT1 and LPCAT2, CG32699, exhibit enlarged LDs in the fat body of the L3 larvae. Furthermore, the data presented suggest that the morphology of LDs is important for the secretion of stored lipids. The reduction of LPCAT1 in liver cells leads to a reduction in lipoprotein particle release. This was shown by measuring the amount of released apolipoproteinB with two different methods, by measuring the release of lipids and by quantification of the amount of released hepatitis C virus, which is known to rely on LD interaction for replication and on lipoprotein particles for cellular release. DGAT2 is recruited to LDs upon excess availability of oleic acid and its overexpression leads to the formation of many, but relatively small LDs. Here, it is shown that DGAT2 interacts with acyl-CoA synthetase ligase 1 (ACSL1), an enzyme that catalyzes the activation of free fatty acids with Coenzyme A. This interaction does not influence the stability of DGAT2 nor does it seem to affect lipid synthesis. Nevertheless, it shows an influence on lipid packaging in LDs. While overexpression of DGAT2 results in the appearance of smaller LDs, overexpression of ACSL1 leads to an increase in LD size. Coexpression of ACSL1 and DGAT2 reverses the phenotypes obtained by single overexpression and normalizes the mean LD diameter to values observed at normal conditions. In conclusion, this thesis shows that LDs are able to synthesize the components of their core and their surface, which underlines their independent function in metabolism. Additionally, the results show that LDs can grow by local synthesis and that the responsible enzymes exhibit a monotopic membrane topology, which might be crucial for LD localization. Furthermore, the obtained data suggest that the localization and the ratio between different enzyme activities influence the packaging of lipids and affects lipid secretion and therefore impact the whole body lipid metabolism.

Genomic aberrations are primary contributors to the pathophysiology of cancer [11]. Dysregulated expression of genes located within these aberrations are important predictors of chemoresistance, disease prognosis, and patient outcome [12]. This dissertation is focused on understanding the regulation and/or functions of specific genes located at dysregulated genomic regions such as 3q26 and 14q32 in the biology of ovarian and renal cancer, respectively. Serous epithelial ovarian cancer (EOC) manifest amplification at the 3q26.2 locus [2], an observation consistent with the cancer genome atlas (TCGA) [13]. The most amplified gene in this region is EVI1 which has been extensively studied in hematological malignancies [2]. However, its contribution to the pathophysiology of solid cancers remains unknown. We hypothesized that dysregulated EVI1 and SnoN/SkiL expression (located at the 3q26.2 amplicon) leads to the altered cellular functional response, thereby contributing to the pathophysiology of ovarian cancer. Our group has previously shown that EVI1 splice forms may exhibit altered subcellular localization and functional properties relative to the wild type form [14]. In Chapter 3 of this dissertation, we identified that EVI1 splice forms could modulate epithelial-mesenchymal transition. Our findings indicate that siRNA construct targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1, (reduces the expression of MDS1/EVI1 and EVI1Del190-515 splice forms) increases epithelial cell markers while decreasing mesenchymal markers and reducing migratory potential of ovarian and breast cancer cells. SnoN/SkiL, another gene overexpressed at the 3q26 is reported by our group to be induced upon As2O3 treatment in ovarian cancer cells via unknown mechanisms [15]. This induction of SnoN opposes the apoptotic cell death pathway induced by the drug treatment [15]. We have previously identified that the PI3K/AKT pathway (also dysregulated in ovarian cancer [16]) contributes to the up-regulation of SnoN upon treatment with As2O3 [17]. However, SnoN is regulated via multiple mechanisms including post-translational modifications [18]. Additionally, c-Ski (a homolog of SnoN) is regulated post-transcriptionally by numerous miRNAs in cancer cells [19-22]. In Chapter 4, we attempted to identify potential miRNAs that could regulate SnoN expression post-transcriptionally. We discovered that miR-494 reduces both SnoN mRNA and protein levels. Our experimental outcomes also demonstrate that miR-494 further sensitizes ovarian cancer cells to drug treatment. Interestingly, miR-494 is located at the 14q32 region which has been shown to be down-regulated in renal cancers [23]. Several reports indicate miR-494 to be involved in tumor suppressive responses including apoptosis and cell cycle arrest in various cancers [24-26]. However, its role in renal cancer biology remains unknown. We hypothesized that miR-494 elicits a tumor suppressive response in renal cancer cells. Through our studies in Chapter 5, we demonstrate that miR-494 reduces cell viability and increases apoptotic response in renal cancer cells. We also show that miR-494 increases LC3B mRNA and protein levels. A 3’UTR luciferase assay indicated that LC3B may be a potential target of miR-494. Intracellular lipid droplets (LDs) increased in miR-494 expressing in a LC3B-dependent manner. This was accompanied with reduced intracellular cholesterol content, increased mitochondrial structural disorganization, and altered Drp1 localization. The outcome of our findings have improved our understanding of the regulation and functional response of these genes/miRNAs (EVI1, SnoN, and miR-494) in ovarian and renal cancers. The studies reported in Chapter 5 identified a novel function of miR-494 in increasing LDs and reducing renal cell survival. However, additional studies are warranted to fully understand the underlying mechanism of increased LDs formation in miR-494 expressing cells and the implication of miR-494 and other miRNAs at the 14q32 region in renal cancer biology. In future, these studies will aid in the development of better treatment strategies which will contribute towards the management of cancer.

Apolipoprotein B (apoB) is the main protein of very-low-density lipoprotein (VLDL). As apoB is translated and moves through the secretory pathway, lipids from cytoplasmic lipid droplets (LDs) are added to form VLDL particles. Without adequate lipid availability, apoB is misfolded and undergoes proteasomal degradation; however, evidence now shows that apoB can be degraded through autophagy. Inhibiting autophagy decreased apoB localization to autophagosomes in HepG2 cells, but also decreased apoB recovered from cells and media. Inducing autophagy increased apoB localization to autophagosomes and decreased apoB recovery. LDs are also degraded through autophagy however LDs were not affected by autophagy modulation in HepG2 cells. In primary hamster hepatocytes, inhibiting autophagy reduced apoB-autophagosome co-localization and increased LD numbers. These data suggest that autophagy may play a complex role in VLDL assembly by regulating degradation of both apoB and LDs. This dual role is more evident in primary hepatocytes indicating a potential physiological role.

Apolipoprotein B (apoB) is the main protein of very-low-density lipoprotein (VLDL). As apoB is translated and moves through the secretory pathway, lipids from cytoplasmic lipid droplets (LDs) are added to form VLDL particles. Without adequate lipid availability, apoB is misfolded and undergoes proteasomal degradation; however, evidence now shows that apoB can be degraded through autophagy. Inhibiting autophagy decreased apoB localization to autophagosomes in HepG2 cells, but also decreased apoB recovered from cells and media. Inducing autophagy increased apoB localization to autophagosomes and decreased apoB recovery. LDs are also degraded through autophagy however LDs were not affected by autophagy modulation in HepG2 cells. In primary hamster hepatocytes, inhibiting autophagy reduced apoB-autophagosome co-localization and increased LD numbers. These data suggest that autophagy may play a complex role in VLDL assembly by regulating degradation of both apoB and LDs. This dual role is more evident in primary hepatocytes indicating a potential physiological role.

Les rhabdomyolyses correspondent à la destruction de fibres musculaires striées squelettiques et mettent en jeu le pronostic vital. La principale cause génétique est liée à un défaut d’oxydation des acides gras ; néanmoins, plus de la moitié des cas n’ont pas de cause identifiée. En 2008, des mutations du gène LPIN1 ont été rapportées comme une nouvelle étiologie de rhabdomyolyse de transmission autosomique récessive. La protéine lipin1 a une double fonction : un rôle de PAP1 intervenant dans la synthèse du triacylglycérol et des phospholipides membranaires ; un rôle de co-activateur transcriptionnel en association avec les PPARs et PGC1α pour réguler de nombreux gènes impliqués dans le métabolisme, dont certains de l’OAG. Lipin1 a deux homologues, lipin2 et lipin3, qui possèdent une activité PAP1 et un site de fixation à des récepteurs nucléaires tels que les PPARs. Nous avons montré que les mutations de LPIN1 rendent compte de plus de 50% des cas de rhabdomyolyse sévère de la petite enfance, une fois écarté le diagnostic de déficit de l’OAG. Une délétion intragénique en phase a été fréquemment identifiée chez les Caucasiens. Nous avons montré qu’il s’agissait d’un probable effet fondateur et que cette délétion est délétère. En effet, à l’inverse de la forme normale de lipin1, la forme délétée est incapable de complémenter la levure pah1, déficiente pour l’homologue de LPIN1. Nous avons ensuite étudié, dans une série de 171 patients, l’implication de LPIN1 dans des pathologies musculaires moins sévères, ainsi que le rôle des deux homologues LPIN2 et LPIN3. Les mutations de LPIN1 sont impliquées dans les rhabdomyolyses sévères et précoces uniquement et les accès de rhabdomyolyse ont toujours un facteur déclenchant, le principal étant les infections aiguës fébriles. Aucune altération majeure de LPIN2 et de LPIN3 n’a été identifiée, même dans des phénotypes modérés. Enfin, nous avons cultivé des myoblastes et des myotubes de patients avec mutations de LPIN1 afin d’étudier les mécanismes de rhabdomyolyse. Les myoblastes déficients en lipin1 ont une activité PAP1 très diminuée et une accumulation de gouttelettes lipidiques. Le niveau d’expression des gènes cibles des facteurs de transcription co-activés par lipin1 (PPARδ, PPARα, PGC1α, ACADVL, CPT1B and CPT2) sont inchangés par rapport aux contrôles, alors que le niveau de lipin2 est augmenté. L’analyse transcriptomique sur cultures de myotubes a identifié chez les patients 19 gènes sous-exprimés et 51 sur-exprimés, notamment ACACB, qui code pour Accβ, enzyme clé de la balance synthèse d’acides gras/OAG. L’invalidation d’ACACB par siRNA dans des myoblastes déficients en lipin1 diminue le nombre de gouttelettes lipidiques, confirmant le lien entre la sur-expression d’ACACB et l’accumulation d’acides gras libres chez les patients. Cependant, le taux de malonyl-CoA, produit d’Accβ, et l’activité CPT1 (étape limitatrice de l’OAG, inhibée par le malonyl-CoA), sont comparables entre myoblastes de patients et de contrôles. Néanmoins, le traitement des cultures par l’association de tumor necrosis factor alpha et d’interleukine-1 β, choisis pour simuler les conditions pro-inflammatoires des infections aiguës, entraîne une augmentation encore plus poussée du taux de malonyl-CoA, une diminution de l’activité CPT1 et une augmentation de l’accumulation de gouttelettes lipidiques chez les patients. Au total, nos données placent LPIN1 comme une cause importante de rhabdomyolyse héréditaire. Le déficit en lipin1 entraine une perturbation du métabolisme lipidique, via une sur-expression d’ACACB, qui est exacerbée en conditions pro-inflammatoires. Nos résultats suggèrent que les conséquences du déficit en lipin1 sont compensées par des mécanismes d'adaptation suffisants en condition normale, mais insuffisants pour la demande métabolique induite par des stress environnementaux comme l'infection, conduisant aux rhabdomyolyses. / Rhabdomyolyses correspond to the destruction of skeletal muscular fibers and are possibly life-threatening. The main genetic cause is linked to defects of fatty acid oxidation (FAO) ; nevertheless, half of the cases have no identified aetiology. In 2008, mutations of LPIN1 gene have been reported as a new cause of autosomal recessive rhabdomyolysis. Lipin1 protein has a double function : 1) a role of phosphatidate phosphatase 1 (PAP1) involved in synthesis of triacylglycerol and membrane phospholipids ; 2) a role of transcriptional co-activator which regulates, in association with the PPARs (peroxysome-proliferator activated receptor) and PGC1α (PPARγ-coactivator1α), numerous genes involved in the metabolism including some genes encoding FAO enzymes. Lipin1 has got two homologues, lipin2 and lipin3, which have a PAP1 activity and a binding site for nuclear receptors, such as the PPARs. We have shown that LPIN1 mutations account for more than 50% of the cases of severe rhabdomyolysis of early infancy, when FAO defects have been excluded. An intragenic in frame deletion has been frequently identified in Caucasians. We have shown that it probably comes from a founding effect and that this deletion is deleterious. Unlike normal lipin1, deleted lipin1 protein is unable to complement the Δpah1 yeast which is defective for the yeast LPIN1 homolog. In a series of 171 patients, we have further studied the involvement LPIN1 in less severe muscular diseases, as well as the role of the two homologues LPIN2 and LPIN3. LPIN1 mutations are involved only in severe and early rhabdomyolyses and the bouts of rhabdomyolysis always have a triggerring factor, mainly acute febrile infections. No major alteration of LPIN2 and LPIN3 has been identified, even in milder phenotypes. Eventually, we have cultivated myoblasts and myotubes of patients with LPIN1 mutations in order to study the mechanisms of the rhabdomyolysis. Lipin1-deficient myoblasts have a drastically decreased PAP1 activity and an accumulation of lipid droplets. The expression level of target genes of the transcription factors co-activated by lipin1 (PPARδ, PPARα, PGC1α, acyl-Coenzyme A very long chain dehydrogenase (ACADVL), carnitine palmitoyl-transferase 1B and 2 (CPT1B and CPT2)) are similar to controls, whereas the level of lipin2 is increased. Transcriptomic analysis of myotube cultures have identified in patients 19 under-expressed genes and 51 over-expressed ones, notably ACACB, which encodes Accβ (acetyl-CoA carboxylase β), key enzyme of the balance between fatty acid synthesis and FAO. ACACB invalidation by siRNA in lipin1-deficient myoblasts decreases the number of lipid droplets, comforting the link between ACACB over-expression and free fatty acid accumulation in patients. However, the level of malonyl-CoA, product of Accβ, and CPT1 activity (limitative step of FAO, inhibited by malonyl-CoA), are similar between myoblasts of patients and controls. But treatment of the cultures with an association of tumor necrosis factor α and interleukin-1 β (TNFα + IL-1β), chosen for mimicking pro-inflammatory conditions of acute infections, leads to a further increase of the level of malonyl-CoA, a decrease of CPT1 activity and an increase of lipid droplets accumulation in patients. In total, our data show that LPIN1 is an important cause of inherited rhabdomyolysis. Lipin1 deficiency leads to a disturbance of the lipidic metabolism, via ACACB over-expression, which is exacerbated in pro-inflammatory conditions. Our results suggest that the consequences of lipin1 deficiency are counterbalanced by adaptative mechanisms which are sufficient at basal state, but insufficient for the metabolic request induced by environmental stresses, such as infections, leading to the rhabdomyolyses. Next step is the study of adipose tissue and the establishment of the inflammatory signature of the patients, in order to determine if this new disease is an auto-inflammatory pathology.

Les résultats fondamentaux et biocliniques que nous présentons au travers de cette thèse illustrent la difficulté d’évaluer la part liée au virus et celle liée à des facteurs de l’hôte dans l’induction d’une stéatose hépatique chez les patients chroniquement infectés par le HCV. Les données in vitro suggèrent que le virus joue un rôle direct dans l’induction d’une stéatose, notamment par les propriétés de sa protéine de capside, et que la variabilité du virus peut avoir un impact sur l’intensité de cette stéatose. Notre étude bioclinique suggère que la variabilité du virus semble avoir un rôle beaucoup plus modéré in vivo. Ainsi, chez les patients chroniquement infectés par le HCV, les facteurs de l’hôte joueraient un rôle majeur pour moduler le degré de la stéatose associée au virus et de prochaines études seront nécessaires pour établir la nature de ces facteurs. / The results presented in this thesis illustrate the difficulty of assessing the part related to the virus and that related to host factors in the induction of hepatic steatosis in patients chronically infected with HCV. In vitro data suggest that the virus plays a direct role in the induction of steatosis, due to the properties of its capsid protein, and that the variability of the virus can affect the intensity of the steatosis. Our bio-clinical study suggests that this variability seems to have a much more moderate impact in vivo. Thus, in patients chronically infected with HCV, host factors seem to play a major role to modulate the degree of steatosis associated with the virus. Further studies are needed to establish the nature of these factors.

No description available.

No description available.